Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoCath down under

This article was originally published in The Gray Sheet

Executive Summary

Montreal firm announces March 26 the introduction at two centers in Australia of its Arctic Front cryoablation balloon catheter for the treatment of paroxysmal, or episodic, atrial fibrillation. The device is already being used at 34 centers in Europe. CryoCath says it is on track to complete enrollment in its STOP AF pivotal U.S. trial in April, and anticipates a late 2009 PMA approval
Advertisement

Related Content

Research In Brief
Advertisement
UsernamePublicRestriction

Register

MT025939

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel